Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
Sponsor: Women and Infants Hospital of Rhode Island
Summary
The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.
Official title: Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
164
Start Date
2025-05-15
Completion Date
2027-01-01
Last Updated
2025-05-01
Healthy Volunteers
No
Interventions
Methenamine Hippurate
Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.
Typically prescribed oral antibiotic prophylaxis
Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.
Locations (1)
Women & Infants Hospital
Providence, Rhode Island, United States